期刊文献+

Serum level of TSGF,CA242 and CA19-9 in pancreatic cancer 被引量:68

Serum level of TSGF,CA242 and CA19-9 in pancreatic cancer
下载PDF
导出
摘要 AIM: To establish a method to detect the expression of the tumor specific growth factor TSGF, CA242 and CA19-9 in serum and evaluate their value in diagnosis of pancreatic cancer. METHODS: ELISA and Biochemical colorimetric assay were used to detect the serum content of TSGF, CA242 and CA19-9 in 200 normal cases, 52 pancreatitis patients and 96 pancreatic cancer patients. RESULTS: The positive likelihood ratios of TSGF, CA242 and CA19-9 were 5.4, 12.6 and 6.3, respectively, and their negative likelihood ratios were 0.10, 0.19 and 0.17, respectively. With single tumor marker diagnosed pancreatic cancer, the highest sensitivity and specificity of TSGF were 91.6% and 93.5%. In combined test with 3 markers, when all of them were positive, the sensitivity changed to 77.0% and the specificity and the positive predictive value were 100%. The levels of TSGF and CA242 were significantly higher in the patients with pancreatic cancer of head than those in the patients with pancreatic cancer of body, tail and whole pancreas, but the expression of CA19-9 had no correlation with the positions of the pancreatic cancer. The sensitivity of TSGF, CA242 and CA19-9 was increased with the progress in stages of pancreatic cancer. In stage I, the sensitivity of TSGF was markedly higher than CA242 and CA19-9. CONCLUSION: The combined use of TSGF, CA242 and CA19-9 expressions can elevate the specificity for pancreatmc cancer diagnosis. And it shows that it plays an important role to differentiate positions and tissue typing. It is a forepart diagnosis for the pancreatic cancer by combination checking. There is very important correlation between the three markers and the pancreatic cancer. AIM:To establish a method to detect the expression of the tumor specific growth factor TSGF,CA242 and CA19-9 in serum and evaluate their value in diagnosis of pancreatic cancer. METHODS:ELISA and Biochemical colorimetric assay were used to detect the serum content of TSGF,CA242 and CA19-9 in 200 normal cases,52 pancreatitis patients and 96 pancreatic cancer patients. RESULTS:The positive likelihood ratios of TSGF,CA242 and CA19-9 were 5.4,12.6 and 6.3,respectively,and their negative likelihood ratios were 0.10,0.19 and 0.17, respectively.With single tumor marker diagnosed pancreatic cancer,the highest sensitivity and specificity of TSGF were 91.6% and 93.5%.In combined test with 3 markers,when all of them were positive,the sensitivity changed to 77.0% and the specificity and the positive predictive value were 100%.The levels of TSGF and CA242 were significantly higher in the patients with pancreatic cancer of head than those in the patients with pancreatic cancer of body,tail and whole pancreas,but the expression of CA19-9 had no correlation with the positions of the pancreatic cancer.The sensitivity of TSGF,CA242 and CA19-9 was increased with the progress in stages of pancreatic cancer.In stage Ⅰ,the sensitivity of TSGF was markedly higher than CA242 and CA19-9. CONCLUSION:The combined use of TSGF,CA242 and CA19- 9 expressions can elevate the specificity for pancreatic cancer diagnosis.And it shows that it plays an important role to differentiate positions and tissue typing.It is a forepart diagnosis for the pancreatic cancer by combination checking. There is very important correlation between the three markers and the pancreatic cancer.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第11期1675-1677,共3页 世界胃肠病学杂志(英文版)
  • 相关文献

二级参考文献35

  • 1Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW,Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A,Domellof L. International pancreatitis study group. N Engl J Med 1993; 328:1433-1437.
  • 2Apple SK, Hecht JR,Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of k-ras,p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis.Hum Pathol 1999; 30:123-129.
  • 3Lee JG, Leung J. Tissue sampling at ERCP in suspected pancreatic cancer. Gastrointest Endosc Clin N Am 1998; 8:221-235.
  • 4Gress F, Gottlieb K, Sherman S, Lehman G. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer. Ann Intern Med 2001; 134:459-464.
  • 5Nakaizumi A, Tatsuta M, Uehara H, Yamamoto R, Takenaka A,Kishigami Y, Takemura K, Kitamura T, Okuda S. Cytologic examination of pure pancreatic juice in the diagnosis of pancreaticcarcinoma. The endoscopic retrograde intraductal catheter aspiration cytologic technique. Cancer 1992; 70:2610-2614.
  • 6Farini R, Fabris C, Bonvicini P, Piccoli A, del Favero G, Venturini R, Panucci A, Naccarato R. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol 1985; 21:429-432.
  • 7Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, Toskes PP. Related Articles, Links Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343-349.
  • 8Safi F, Beger HG, Bittner R, Bucher M, Krautzberger W. CA19-9 and pancreatic adenocarcinoma. Cancer 1986; 57:779-783.
  • 9Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo ISK,Min YI. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer.analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94:1941-1946.
  • 10Wakasugi H, Funakoshi A, Iguchi H, Takase M, Inoue M,Ohshima A, Seo Y. Pancreatic carcinoma associated with chronic pancreatitis. Intern Med 1999; 38:951-956.

共引文献4

同被引文献269

引证文献68

二级引证文献292

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部